A User's Guide to the NINDS rt-PA Stroke Trial Database
article has not abstract
Vyšlo v časopise:
A User's Guide to the NINDS rt-PA Stroke Trial Database. PLoS Med 5(5): e113. doi:10.1371/journal.pmed.0050113
Kategorie:
Guidelines and Guidance
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.0050113
Souhrn
article has not abstract
Zdroje
1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
1995
Tissue plasminogen activator for acute ischemic stroke.
N Eng J Med
333
1581
1587
2. American Heart Association in Collaboraton with the International Liason Committee on Rususcitation
2000
Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 7: The era of reperfusion: Section 2: Acute stroke.
Circulation
102
suppl I
1204
1216
3. Quality Standards Subcommittee of the American Academy of Neurology, Practice Advisory
1996
Thrombolytic therapy for acute ischemic stroke: Summary statement.
Neurology
47
835
839
4. HoffmanJR
2001
Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative.
Can J Emerg Med
3
183
185
5. HoffmanJR
2000
Should physicians give tPA to patients with acute ischemic stroke? Against: And just what is the emperor of stroke wearing.
West J Med
173
149
150
6. HoffmanJR
2003
Tissue plasminogen activator (tPA) for acute ischaemic stroke: Why so much has been made of so little.
Med J Aust
179
333
334
7. MannJ
2002
Truths about the NINDS study: Setting the record straight.
West J Med
176
192
194
8. TrotterG
2002
Why were the benefits of tPA exaggerated? The role of interpretation bias.
West J Med
176
194
197
9. HaleyECLewandowskiCTilleyB
NINDS rt-PA Stroke Study Group
1997
Myths regarding the NINDS rt-PA Stroke Trial: Setting the record straight.
Ann Emerg Med
30
676
682
10. RobinsonDJ
2000
Should physicians give tPA to patients with acute ischemic stroke? For: Thrombolytics in stroke: Whose risk is it anyway.
West J Med
173
148
9
11. LattimoreSUChalelaJDavisLDeGrabaTEzzeddineM
2003
Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: The NINDS Suburban Hospital Stroke Center experience.
Stroke
34
e55
e57
12. LenzerJ
2002
Alteplase for stroke: Money and optimistic claims buttress the “brain attack” campaign.
BMJ
324
723
729
13. BroderickJLuMJacksonCPancioliATilleyB
2001
Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.
Ann Neurol
49
736
744
14. BroderickJPLuMKothariRLevineSRLydenPD
2000
Finding the most powerful measures of t-PA's effectiveness in the NINDS t-PA Stroke Trial.
Stroke
31
2335
2341
15. BrottTLuMKothariRFaganSCFrankelM
1998
Hypertension and its treatment in the NINDS rt-PA Stroke Trial.
Stroke
29
1504
1509
16. BrunoALevineSRFrankelMRBrottTGLinY
2002
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.
Neurology
59
669
674
17. FaganSCMorgensternLBPetittaAWardRETilleyBC
1998
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke.
Neurology
50
883
890
18. FrankelMMorgensternLBKwiatkowskiTLuMTilleyBC
2000
Predicting prognosis after stroke: A placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Neurology
55
952
959
19. GrottaJWelchKMAFaganSLuMFrankelM
2001
Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.
Stroke
32
661
668
20. KwiatkowskiTGLibmanRBFrankelMTilleyBCMorgensternLB
1999
Effects of tissue plasminogen activator for acute ischemic stroke at one year.
N Eng J Med
340
1781
1787
21. KwiatkowskiTLibmanRTilleyBCLewandowskiCGrottaJ
2005
The impact of imbalances in baseline stroke severity on outcome in the NINDS rt-PA Stroke Study.
Ann Emerg Med
45
377
384
22. LuMLydenPDBrottTGHamiltonSBroderickJP
2005
Beyond subgroup analysis: Improving the clinical interpretation of treatment effects in stroke research.
J Neurosci Methods
143
209
216
23. LuM
Tilley BC; the NINDS t-PA Stroke Trial Study Group
2001
Use of odds ratio or relative risk to measure a treatment effect in clinical trials with multiple correlated binary outcomes: Data from the NINDS t-PA Stroke Trial.
Stat Med
20
1891
1901
24. LuMTilleyBCLiS
1998
Issues on permutation tests: Applications in analysis of CT lesion volume in the NINDS T-PA Stroke Trial.
In
ASA Proceedings of the Biopharmaceutical Section
27
32
Alexandria (VA)
American Statistical Association
25. LydenLLuMJacksonCMarlerJKothariR
1999
Underlying structure of the NIH Stroke Scale: Results of factor analysis.
Stroke
30
2347
2354
26. LydenPLuMKwiatkowskiTFrankelMLevineS
2001
Thrombolysis in patients with transient neurologic deficits.
Neurology
57
2125
2128
27. LydenPLuMLevineSBrottTBroderickJ
2001
A modified National Institutes of Health Stroke Scale for use in stroke clinical trials.
Stroke
32
1310
1317
28. MarlerJRTilleyBCLuMBrottTGLydenPC
2000
Early stroke treatment associated with better outcome.
Neurology
55
1649
1655
29. PatelSCLevineSRTilleyBCGrottaJCLuM
2001
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
JAMA
286
2830
2838
30. TanneDLevineSRBreyRLLinHFaganSC
2003
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial.
Neurology
61
1158
1159
31. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators
2004
Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA Stroke Trials.
Lancet
363
768
774
32. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group
1997
A systems approach to immediate evaluation and management of hyperacute stroke: Experience at eight centers and implications for community practice and patient care.
Stroke
28
1530
1540
33. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group
2000
Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography.
Stroke
31
2912
2919
34. The NINDS t-Pa Stroke Study Group
1997
Generalized efficacy of t-PA for acute stroke: Subgroup analysis of the NINDS t-PA Stroke Study.
Stroke
28
2119
2125
35. The NINDS t-Pa Stroke Study Group
1997
Intracerebral hemorrhage following intravenous t-PA therapy for ischemic stroke.
Stroke
28
2109
2118
36. The NINDS rt-PA Stroke Study Group
2005
Recombinant tissue plasminogen activator for minor strokes: The National Institute of Neurological Disorders and Stroke rt-PA Stroke study experience.
Ann Emerg Med
46
243
252
37. TilleyBCMarlerJGellerNLuMLeglerJ
1996
Use of a global test for multiple outcomes in stroke trials with application to the NINDS t-PA Stroke Trial.
Stroke
27
2136
2141
38. WooDBroderickJKothariRLuMBrottT
1999
Does National Institutes of Health Stroke Scale (NIHSS) favor left hemisphere stroke.
Stroke
30
2355
2359
39. IngallTJO'FallenWMAspludKGoldfrankLRHertzbergVS
2004
Findings from the reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial.
Stroke
35
2418
2424
40. SaverJLYafehB
2007
Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA Stroke Trials.
Stroke
38
414
416
41. HoffmanJRSchrigerDL
2007
Impact of treatment on individual patients in the NINDS Trial: A graphic representation based on change in NIHSS Score [abstract].
38th American College of Emergency Physicians Research Forum; 8–11 October 2007; Seattle, Washington, United States
42. IoannidisJPA
2005
Contradicted and initially stronger effects in highly cited clinical research.
JAMA
294
218
228
43. WardlawJMdel ZoppoGYamaguchiTBergeE
2006
Thrombolysis of acute ischemic stroke (Cochrane Review).
In
The Cochrane Library
Issue 3
Chichester (UK)
John Wiley and Sons
44. KatzanILFurlanAjLloydLEFrankJIHarperDL
2000
Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience.
JAMA
283
1151
1158
45. BravataDMKimeNConcatoJKrumholzHMBrassLM
2002
Thrombolysis for acute stroke in routine clinical practice.
Arch Intern Med
162
1994
2001
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2008 Číslo 5
- Statiny indukovaná myopatie: Jak na diferenciální diagnostiku?
- Pleiotropní účinky statinů na kardiovaskulární systém
- Hydroresponzivní krytí v epitelizační fázi hojení rány
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Intermitentní hladovění v prevenci a léčbě chorob
Najčítanejšie v tomto čísle
- Disease Mongering Is Now Part of the Global Health Debate
- Communicating the Results of Clinical Research to Participants: Attitudes, Practices, and Future Directions
- A User's Guide to the NINDS rt-PA Stroke Trial Database
- Expectations for Recovery Important in the Prognosis of Whiplash Injuries